Holt Patrick
Known title: President and CEOCIK: 0001986374
Holt Patrick's purchase track record
Holt Patrick has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/22/2024 | AMRN | $16K | -24.3% | -31.3% | +14.7% |
| 8/16/2023 | AMRN | $312K | -29.3% | +11.3% | +13.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| AMRN | ▲ Buy | Open Market | 14,426 | $16K | 1/22/2024 | View on chart |
| AMRN | ▲ Buy | Open Market | 958 | $982 | 8/16/2023 | View on chart |
| AMRN | ▲ Buy | Open Market | 143,275 | $148K | 8/16/2023 | View on chart |
| AMRN | ▲ Buy | Open Market | 19,358 | $20K | 8/16/2023 | View on chart |
| AMRN | ▲ Buy | Open Market | 30,642 | $32K | 8/16/2023 | View on chart |
| AMRN | ▲ Buy | Open Market | 12,700 | $13K | 8/16/2023 | View on chart |
| AMRN | ▲ Buy | Open Market | 25,845 | $27K | 8/16/2023 | View on chart |
| AMRN | ▲ Buy | Open Market | 67,222 | $71K | 8/16/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Amarin (AMRN) sees competition as Teva pushes branded drugs
Teva Pharmaceutical announced that branded drugs will be a central part of its growth plan. This focus highlights the competitive environment for other companies with specialty branded products, such as Amarin’s Vascepa. The news may influence market perception of Amarin’s positioning within the branded drug space.
Amarin (AMRN) sees competition as Teva pushes branded drugs. Teva Pharmaceutical announced that branded drugs will be a central part of its growth plan. This focus highlights the competitive environment for other companies with specialty branded products, such as Amarin’s Vascepa. The news may influence market perception of Amarin’s positioning within the branded drug space.